[1] Orozco-Morales M, Soca-Chafre G, Barrios-Bernal P, et al.Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer[J]. Mediators Inflamm, 2016, 2016: 1-11.
[2] Balkwill F, Mantovani A.Inflammation and cancer: back to Virchow?[J]. Lancet, 2001, 357(9255): 539-545.
[3] Abu-Shawer O, Abu-Shawer M, Hirmas N, et al.Hematologic markers of distant metastases and poor prognosis in gynecological cancers[J]. BMC Cancer, 2019, 19(1): 141.
[4] Rassouli A, Saliba J, Castano R, et al.Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma: Inflammatory Markers in Head and Neck Malignancies[J]. Head Neck, 2015, 37(1): 103-110.
[5] Fang L, Xu X, Ji Y, et al.The Prognostic Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Resected Patients with Pancreatic Adenocarcinoma[J]. World J Surg, 2018, 42(11): 3736-3745.
[6] Azab B, Shah N, Radbel J, et al.Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients[J]. Med Oncol, 2013, 30(1): 432.
[7] Pirozzolo G, Gisbertz SS, Castoro C, et al.Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis[J]. J Thorac Dis, 2019, 11(7): 3136-3145.
[8] Cummings M, Merone L, Keeble C, et al.Preoperative neutrophil: lymphocyte and platelet: lymphocyte ratios predict endometrial cancer survival[J]. Br J Cancer, 2015, 113(2): 311-320.
[9] Haruma T, Nakamura K, Nishida T, et al.Pre-treatment Neutrophil to Lymphocyte Ratio Is a Predictor of Prognosis in Endometrial Cancer[J]. Anticancer Res, 2015, 35(1): 337-343.
[10] Holub K, Busato F, Gouy S, et al.Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External Radiotherapy[J]. J Clin Med, 2020, 9(5): 1441.
[11] Ding L, Ding Y, Mao X, et al.Retrospective study of the prognostic significance of neutrophil, to, lymphocyte ratio for postsurgical outcomes of patients with endometrial carcinoma[J]. Int J Gynaecol Obstet, 2017, 138(3): 311-319.
[12] Ni L, Tao J, Xu J, et al.Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta- analysis[J]. Arch Gynecol Obstet, 2020, 301(1): 251-261.
[13] Temur I, Gulec UK, Paydas S, et al.Prognostic value of pre-operative neutrophil/ lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 226: 25-29.
[14] Li J, Lin J, Luo Y, et al.Multivariate Analysis of Prognostic Biomarkers in Surgically Treated Endometrial Cancer[J]. PLoS One, 2015, 10(6), 1-11.
[15] Cömert GK, Türkmen O, Kar İ, et al.Independent predictors of survival in endometrium cancer:platelet-to-lymphocyte ratio and platelet/neutrophil/monocyte-to-lymphocyte ratio[J]. J Turk Ger Gynecol Assoc, 2018, 19(2): 78-86.
[16] Kurtoglu E, Kokcu A, Celik H, et al.Platelet Indices May be Useful in Discrimination of Benign and Malign Endometrial Lesions, and Early and Advanced Stage Endometrial Cancer[J]. Asian Pac J Cancer Prev, 2015, 16(13): 5397-5400.
[17] Eo WK, Kwon S, Koh SB, et al.The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial Cancer[J]. J Cancer, 2016, 7(5): 538-545.
[18] Cong R, Kong F, Ma J, et al.Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer[J]. BMC Cancer, 2020, 20(1): 464.
[19] Kwon BS, Lee HJ, Yang J, et al.Prognostic value of preoperative lymphocyte-monocyte ratio in elderly patients with advanced epithelial ovarian cancer[J]. Obstet Gynecol Sci, 2017, 60(6): 558-564.
[20] Kwon BS, Jeong DH, Byun JM, et al.Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma[J]. J Cancer, 2018, 9(7): 1127-1134.
[21] Eo WK, Chang HJ, Kwon SH, et al.The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer[J]. J Cancer, 2016, 7(3): 289-296.
[22] Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al.Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer[J]. J Gynecol Oncol, 2012, 23(4): 265-273.
[23] Miao Y, Yan Q, Li S, et al.Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy[J]. Cancer Biomark, 2016, 17(1): 33-40.
[24] Yang Z, Gu JH, Guo CS, et al.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies[J]. Oncotarget, 2017,8(28): 46414-46424.
[25] Zhu Y, Zhou S, Liu Y, et al.Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review[J]. BMC Cancer, 2018, 18(1): 443.
[26] Marchetti C, Romito A, Musella A, et al.Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role?[J]. Int J Gynecol Cancer, 2018, 28(5): 939-944.
[27] Yildirim MA, Seckin KD, Togrul C, et al.Roles of Neutrophil/Lymphocyte and Platelet/ Lymphocyte Ratios in the Early Diagnosis of Malignant Ovarian Masses[J]. Asian Pac J Cancer Prev, 2014, 15(16): 6881-6885.
[28] Topcu HO, Guzel AI, Ozer I, et al.Comparison of Neutrophil/Lymphocyte and Platelet/ Lymphocyte Ratios for Predicting Malignant Potential of Suspicious Ovarian Masses in Gynecology Practice[J]. Asian Pac J Cancer Prev, 2014, 15(15): 6239-6241.
[29] Zhu M, Feng M, He F, et al.Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer[J]. Clin Chim Acta, 2018, 483: 296-302.
[30] Kozasa K, Mabuchi S, Komura N, et al.Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review[J]. Oncotarget, 2017, 8(33): 55394-55404.
[31] Zhang Y, WANG L, LIU Y, et al.Preoperative Neutrophil-Lymphocyte Ratio Before Platelet -Lymphocyte Ratio Predicts Clinical Outcome in Patients With Cervical Cancer Treated With Initial Radical Surgery[J]. Int J Gynecol Cancer, 2014, 24(7): 1319-1325.
[32] Nakamura K, Nakayama K, Tatsumi N, et al.Prognostic significance of pre-treatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in non-surgically treated uterine cervical carcinoma[J]. Mol Clin Oncol, 2018, 9(2): 138-144.
[33] Jonska-Gmyrek J, Gmyrek L, Zolciak-Siwinska A, et al.Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients[J]. Cancer Manag Res, 2018, 10: 6029-6038.
[34] Wang D, Wu M, Feng FZ, et al.Pretreatment neutrophil-to-lymphocyte and platelet-to- lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy[J]. Chin Med J (Engl), 2013, 126(8): 1464-1468.
[35] Kose M, Celik F, Kose SK, et al.Could the Platelet-to-Lymphocyte Ratio be a Novel Marker for Predicting Invasiveness of Cervical Pathologies?[J]. Asian Pac J Cancer Prev, 2015, 16(3): 923-926.
[36] Prabawa IPY, Bhargah A, Liwang F, et al.Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer[J]. Asian Pac J Cancer Prev, 2019, 20(3): 863-868.
[37] Mizunuma M, Yokoyama Y, Futagami M, et al.The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J]. Int J Clin Oncol, 2015, 20(5): 989-996
[38] Ethier JL, Desautels DN, Templeton AJ, et al.Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta- analysis[J]. Gynecol Oncol, 2017, 145(3): 584-594. |
